6 research outputs found
Validation of circulating steroid hormone measurements across different matrices by liquid chromatography–tandem mass spectrometry
Background: Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid measurements are sensitive to bias
High-throughput isolation of circulating tumor DNA
The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical
trials has necessitated the development of a high-throughput method for fast,
reproducible, and efficient isolation of ctDNA. Currently, the majority of
ctDNA studies use the manual QIAamp (QA) platform to isolate DNA from
blood. The purpose of this study was to compare two competing automated
DNA isolation platforms [Maxwell (MX) and QIAsymphony (QS)] to the current ‘gold standard’ QA to facilitate high-throughput processing of samples in
prospective trials. We obtained blood samples from healthy blood donors and
metastatic cancer patients for plasma isolation. Total cell-free DNA (cfDNA)
quantity was assessed by TERT quantitative PCR. Recovery efficiency was
investigated by quantitative PCR analysis of spiked-in synthetic plant DNA.
In addition, a b-actin fragmentation assay was performed to determine the
amount of contamination by genomic DNA from lysed leukocytes. ctDNA
quality was assessed by digital PCR for somatic variant detection. cfDNA
quantity and recovery efficiency were lowest using the MX platform, whereas
QA and QS showed a comparable performance. All platforms preferentially
isolated small (136 bp) DNA fragments over large (420 and 2000 bp) DNA
fragments. Detection of the number variant and wild-type molecules was most
comparable between QA and QS. However, there was no significant difference
in variant allele frequency comparing QS and MX to QA. In summary, we
show that the QS platform has comparable performance to QA, the ‘gold
standard’, and outperformed the MX platform depending on the readout
used. We conclude that the QS can replace the more laborious QA platform,
especially when high-throughput cfDNA isolation is needed
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions
Circulating tumor DNA (ctDNA) has emerged as a potential new biomarker with diagnostic, predictive, and prognostic applications for various solid tumor types. Before beginning large prospective clinical trials to prove the added value of utilizing ctDNA in clinical practice, it is essential to investigate the effects of various preanalytical conditions on the quality of cell-free DNA (cfDNA) in general and of ctDNA in particular in order to optimize and standardize these conditions. Whole blood samples were collected from patients with metastatic cancer bearing a known somatic variant. The following preanalytical conditions were investigated: (a) different time intervals to plasma isolation (1, 24, and 96 h) and (b) different preservatives in blood collection tubes (EDTA, CellSave, and BCT). The quality of cfDNA/ctDNA was assessed by DNA quantification, digital polymerase chain reaction (dPCR) for somatic variant detection and a β-actin fragmentation assay for DNA contamination from lysed leukocytes. In 11 (69%) of our 16 patients, we were able to detect the known somatic variant in ctDNA. We observed a time-dependent increase in cfDNA concentrations in EDTA tubes, which was positively correlated with an increase in wild-type copy numbers and large DNA fragments (> 420 bp). Using different preserva
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA) to enrich CTCs from patients with metastatic prostate cancer (mPCa) and explored whether organoids provide a platform for ex vivo treatment modelling. Methods: We prospectively screened 102 patients with mPCa and performed DLA in 40 patients with ≥5 CTCs/7.5 mL blood. We enriched CTCs from DLA using white blood cell (WBC) depletion alone or combined with EpCAM selection. The enriched CTC samples were cultured in 3D to obtain organoids and used for downstream analyses. Results: The DLA procedure resulted in a median yield of 5312 CTCs as compared with 22 CTCs in 7.5 mL of blood. Using WBC depletion, we recovered 46% of the CTCs, which reduced to 12% with subsequent EpCAM selection. From the isolated and enriched CTC samples, organoid expansion succeeded in 35%. Successful organoid cultures contained significantly higher CTC numbers at initiation. Moreover, we performed treatment modelling in one organoid cell line and identified substantial tumour heterogeneity in CTCs using single cell DNA sequencing. Conclusions: DLA is an efficient method to enrich CTCs, although the modest success rate of culturing CTCs precludes large scale clinical application. Our data do suggest that DLA and subsequent processing provides a rich source of viable tumour cells. Therefore, DLA offers a promising alternative to biopsy procedures to obtain sufficient number of tumour cells to study sequential samples in patients with mPCa. Trial registration number: NL6019.</p
Reversibility of neuropathology and motor deficits in an inducible mouse model for FXTAS
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting carriers of the fragile X-premutation, who have an expanded CGG repeat in the 5